Scope and claims for US Patent 10,272,079: phosphate uptake inhibition for hyperphosphatemia and patent landscape implications
US Patent 10,272,079 is directed to enteral administration of a compound (and optionally a pharmaceutically acceptable salt) to inhibit phosphate uptake in the gastrointestinal (GI) tract for patients needing phosphate lowering, with dependent claim coverage that expands into hyperphosphatemia treatment and combination therapy with phosphate binders. The practical effect of the claim set is to create method-of-treatment and method-of-use coverage that can constrain both monotherapy and combination regimens in nephrology and GI-relevant phosphate control settings, including postprandial hyperphosphatemia.
What is US Patent 10,272,079 claiming at a high level?
Core independent claims (as provided):
- Claim 1: A method for inhibiting phosphate uptake in the GI tract by enterally administering an effective amount of “the compound” to a patient needing phosphate lowering.
- Claim 3: A method for treating hyperphosphatemia by administering an effective amount of the compound or a pharmaceutically acceptable salt.
Key dependent claim themes (as provided):
- Salt-dependent limitation (claims 2 and 4): salt forms of the compound are claim-locked to a specified salt type list (content not shown in the excerpt).
- Combination therapy (claims 5 to 14): adding an additional biologically active agent, where that agent is specifically a phosphate binder.
- Phosphate binder subgroup coverage:
- Broader binder list (claims 7 and 12): includes multiple classes (sevelamer salts, lanthanum carbonate, calcium salts, ferric citrate, magnesium iron hydroxycarbonate, aluminum hydroxide, plus labeled or code-named binders such as MCI-196, APS1585, SBR-759, PA-21).
- Narrower binder list (claims 8 and 13): subset coverage (includes combinations like calcium acetate/magnesium carbonate and excludes certain broader list items).
- Most narrow binder subgroup (claims 9 and 14): targets sevelamer (and sevelamer carbonate and sevelamer hydrochloride).
- Indication timing (claim 15): explicitly includes postprandial hyperphosphatemia.
Claim architecture implication: The estate is built around (1) a GI uptake inhibition mechanism method claim, (2) a direct hyperphosphatemia treatment method claim, and (3) combination-dependent claims that tie the compound to the standard-of-care phosphate binder portfolio. This structure can support infringement theories both for branded use instructions and for real-world combo regimens even when the compound is dosed with a separate binder product.
What patents protect phosphate uptake inhibition for hyperphosphatemia in the US?
This US patent’s claim set (as provided) is narrower than a broad “phosphate lowering” platform patent because it is anchored to:
- inhibiting phosphate uptake in the GI tract, and
- enteral administration, and
- (in dependent claims) combination with specific phosphate binders.
Mechanism claim scope: how close do products need to match?
From the text you provided, infringement risk is driven by meeting all of the following practical elements:
- GI tract phosphate uptake inhibition: accused method must reduce phosphate absorption/uptake in the GI tract using the compound.
- Enteral administration: dosing must be oral/enteral rather than parenteral.
- Effective amount: standard method-of-treatment language that will be litigated on dose and exposure.
- Patient population: “patient in need of phosphate lowering” includes hyperphosphatemia populations, and claim 15 covers postprandial hyperphosphatemia.
Treatment claim scope: what patient and indication is covered?
- Claim 3 covers hyperphosphatemia treatment generally.
- Claim 15 narrows to postprandial hyperphosphatemia, which is a specific timing/physiology slice: it captures regimens designed to control phosphate spikes after food intake, a key commercial use case in CKD patients and dialysis-related care.
How broad is the enteral method claim (Claim 1) versus the hyperphosphatemia method (Claim 3)?
Claim 1 (phosphate uptake inhibition) is mechanism-tethered to GI absorption physiology. It can be asserted where the compound’s claimed or operational effect is tested/validated as phosphate uptake inhibition in GI tract.
Claim 3 (hyperphosphatemia treatment) is outcome-tethered. It is often easier to map to clinical use because it does not require proving the mechanism in the GI tract to the same degree, depending on claim construction. That said, in practice, claim 3 and claim 1 are likely read together because the same compound and the same GI uptake inhibition theme appear across the set.
Practical coverage takeaway: the estate covers both “how it works” (Claim 1) and “what it does” (Claim 3), which increases enforcement flexibility.
What does the salt limitation do to the claim scope (Claims 2 and 4)?
You provided the claim language that the salt is “pharmaceutically acceptable,” but the excerpt does not show the salt identity list referenced in claims 2 and 4.
Legal consequence of salt-dependent claims (mechanics):
- If a competitor’s formulation uses a salt form not within the claim’s defined salt category, it may avoid dependent claim coverage.
- Claim 3 still covers the “compound or pharmaceutically acceptable salt thereof,” which can be broader than a dependent claim with a narrower salt list. How broad depends on what “salt is” means in claim drafting.
Business impact: salt selection is a controllable formulation lever; it can narrow or eliminate combination-therapy risk if the dependent claims are asserted.
What phosphate binders are explicitly covered in the combination claims?
The combination claims in claims 5 to 14 are pivotal because they name phosphate binder actives (and in some cases binder product families/codes). Based on your provided excerpt:
Broader binder set in claims 7 and 12 (extended list)
Includes:
- Sevelamer
- Sevelamer carbonate
- Sevelamer hydrochloride
- Lanthanum carbonate
- Calcium carbonate
- Calcium acetate
- Magnesium carbonate
- MCI-196
- Ferric citrate
- Magnesium iron hydroxycarbonate
- Aluminum hydroxide
- APS1585
- SBR-759
- PA-21
Narrower binder sets in claims 8 and 13 (subset list)
Includes:
- Sevelamer carbonate
- Lanthanum carbonate
- Calcium carbonate
- Calcium acetate
- Calcium acetate/magnesium carbonate
- Ferric citrate
- Magnesium iron hydroxycarbonate
- Aluminum hydroxide
Most narrow sevelamer-only subgroup in claims 9 and 14
Includes:
- Sevelamer
- Sevelamer carbonate
- Sevelamer hydrochloride
Claiming effect of binder lists
These lists convert the combination method into something closer to a covered regimen map:
- If the compound is dosed together with a named binder (within the boundaries of the “further comprising administering” language), the method can fall into dependent claim territory.
- If a competitor uses a phosphate binder outside the listed set, it may reduce dependent claim exposure. Independent claims 1 and 3 remain, so monotherapy exposure persists.
Does the patent cover postprandial hyperphosphatemia specifically?
Yes. Claim 15 expressly covers:
- Hyperphosphatemia is postprandial hyperphosphatemia.
Interpretive consequence: If the compound is positioned as an agent to blunt phosphate rise after meals, claim 15 gives the patent a direct hook into that specific clinical and commercial narrative. It also supports infringement arguments tied to dosing timing and diet-driven phosphate fluctuations.
What is the likely infringement boundary for combination therapy?
Based on claim structure (“further comprising administering an additional biologically active agent” and specifying phosphate binder selection), key boundaries are:
- Co-administration vs. sequential dosing: the claim language you provided does not specify timing. In litigation, claim construction will determine whether sequential dosing counts as “comprising administering.” From a risk perspective, any regimen that is understood as a treatment plan including both actives is exposed.
- Choice of binder: exposure scales with binder selection. The named binder lists create clear categories of covered regimens.
- Patient state: patient must be “in need of phosphate lowering” or “in need” of hyperphosphatemia treatment. That generally aligns with CKD/dialysis-related hyperphosphatemia patient profiles but can be tied more precisely to postprandial episodes under claim 15.
How strong is the patent estate for generic or biosimilar-style entry risk?
This is a small-molecule-style method patent as framed by the provided claim set. It is not a biologics patent type. That matters for enforcement strategy: the major entry risk is typically ANDA-style paragraph IV if an ANDA product is designed to practice the claimed method, or labeling/indication design-around that prevents infringement by avoiding instructions that fall within the patented method claims.
Practical risk zones for competitors
- Direct method infringement: if a competitor markets the compound with instructions that match Claim 1 or Claim 3.
- Induced/contributory theories: if a competitor’s labeling or promotional materials drive use in a way that practices the claims.
- Combination risk: if a competitor’s regimen includes the compound plus one of the listed binders, dependent claims 5 to 14 become relevant.
The role of the binder list in design-around
Competitors can attempt to mitigate dependent claim exposure by:
- pairing with a phosphate binder not on the listed set, and/or
- using different salt forms not covered by the salt-dependent dependent claims (where lists are narrower than claim 3).
Monotherapy exposure from Claims 1 and 3 remains a constraint.
What licensing, settlement, and paragraph IV leverage could exist?
A method patent with named binder combinations can be powerful in settlement because it can target not only the “compound itself” but also specific treatment programs used in practice. The litigation leverage often stems from:
- claim language that matches standard clinical combination patterns, and
- dependent claims that can support narrow injunction requests tied to combination regimens.
What is missing from your excerpt that affects legal scope?
Your excerpt includes the claim skeleton and the phosphate binder lists, but not:
- the identity of the “compound” (active ingredient),
- the full pharmaceutically acceptable salt definitions in claims 2 and 4,
- any formulation details (dosage forms, release profile) if present in the full patent,
- the specification’s preferred mechanism evidence that can affect claim construction.
Because the compound identity and salt list are not shown, only the structural scope can be analyzed from your provided text without adding unverifiable specifics.
Key claim-by-claim scope map (from your excerpt)
| Claim |
Coverage theme |
Required elements (from provided text) |
Enforcement hook |
| 1 |
GI phosphate uptake inhibition |
enterally administer compound effective amount to inhibit phosphate uptake |
mechanism method; dosing route |
| 3 |
Hyperphosphatemia treatment |
administer compound or pharmaceutically acceptable salt |
clinical use/outcome method |
| 5 |
Combination with additional agent |
method of claim 1 + administer additional biologically active agent |
regimen-based infringement |
| 6 |
Additional agent is phosphate binder |
claim 5 + binder |
standard-of-care pairing |
| 7 |
Binder list (broad) |
claim 6 + binder in listed group |
identifies covered binders |
| 8 |
Binder list (subset) |
claim 6 + binder in subset |
narrows dependent coverage |
| 9 |
Sevelamer subgroup |
claim 6 + sevelamer types |
most likely marketed combo |
| 10 |
Combination applies to hyperphosphatemia method |
claim 3 + additional agent |
extends to treatment method combos |
| 11 |
Additional agent is phosphate binder |
claim 10 + binder |
regimen coverage |
| 12 |
Binder list (broad) on claim 11 |
claim 11 + binders in listed group |
dependent breadth |
| 13 |
Binder list (subset) on claim 11 |
claim 11 + subset |
dependent narrowing |
| 14 |
Sevelamer subgroup on claim 11 |
claim 11 + sevelamer types |
most targeted subgroup |
| 15 |
Timing/phenotype |
claim 3 + postprandial hyperphosphatemia |
meal-related dosing/instructions |
Key takeaways
- US 10,272,079 is built around enteral administration of a compound to inhibit GI phosphate uptake and to treat hyperphosphatemia, with explicit coverage for postprandial hyperphosphatemia.
- The combination dependent claims are unusually actionable because they name phosphate binders. Regimens using the compound with sevelamer salts, lanthanum carbonate, calcium salts, ferric citrate, magnesium iron hydroxycarbonate, and aluminum hydroxide fall into specific dependent claim bands.
- The estate supports enforcement against both monotherapy (Claims 1 and 3) and combination regimens (Claims 5 to 14), with sevelamer-only subgroups forming the tightest dependent claim layer.
- Salt scope (Claims 2 and 4) can be a design-around lever, but the exact salt list is not included in the excerpt you provided.
FAQs
1) How do combination-dependent claims change generic launch risk for phosphate lowering drugs?
They can turn otherwise non-infringing monotherapy entry into infringement if the launch labeling, patient instructions, or real-world use includes co-administration with a named phosphate binder.
2) What is the legal significance of “enterally administering” in phosphate uptake inhibition claims?
It narrows infringement to GI-route dosing and can exclude parenteral administration strategies from practicing the claim.
3) Why does a postprandial hyperphosphatemia claim matter commercially?
It ties infringement to meal-timing and post-meal dosing regimens, which affects how companies draft dosing instructions and marketing claims.
4) What design-around levers exist for salt-form dependent claims?
Using a different salt form that is outside the dependent claim salt list (while still achieving the compound’s pharmacologic effect) can avoid dependent claim coverage, though independent claims may still apply.
5) How does binder list specificity impact settlement leverage?
Named binders allow plaintiffs to argue infringement of specific routine treatment combinations, supporting narrower, regimen-targeted claims in licensing or settlement.
References
- US Patent 10,272,079, claims 1-15 (as provided in the prompt).
